The resonance® metallic ureteral stent in the treatment of malignant ureteral obstruction: a prospective observational study

Autor: Satoshi Takahashi, Takuro Masaki, Masahiko Suzuki, Jun Miyazaki, Takahiko Hashimoto, Mizuki Onozawa, Yuka Muramatsu Maekawa, Koichiro Wada, Yuji Maeda, Kensaku Seike, Akito Yamaguchi, Shingo Yamamoto, Tomokazu Kimura, Manabu Takai, Mitsuru Yasuda, Yasuyuki Sakai
Rok vydání: 2019
Předmět:
Male
Malignant ureteral obstruction
Time Factors
Ureteral stent
medicine.medical_treatment
lcsh:RC870-923
urologic and male genital diseases
Primary outcome
Prospective Studies
Gastrointestinal Neoplasms
Aged
80 and over
Bacterial Infections
General Medicine
Middle Aged
Ureteral cancer
Magnetic Resonance Imaging
Prosthesis Failure
Treatment Outcome
surgical procedures
operative
Metals
Creatinine
Female
Stents
Ureteral Stricture
Metallic ureteric stenting
Median survival
Ureteral Obstruction
Research Article
Adult
medicine.medical_specialty
Stent insertion
Genital Neoplasms
Female
Urology
Prosthesis Design
Prosthesis Implantation
Sex Factors
Female patient
medicine
Humans
Metal stent
Aged
Resonance stent
business.industry
Stent
lcsh:Diseases of the genitourinary system. Urology
equipment and supplies
medicine.disease
Surgery
Reproductive Medicine
Observational study
business
Follow-Up Studies
Zdroj: BMC Urology, Vol 19, Iss 1, Pp 1-9 (2019)
BMC Urology
ISSN: 1471-2490
DOI: 10.1186/s12894-019-0569-y
Popis: Background To study the outcomes and experiences of using metallic stents in treating patients with malignant ureteral obstruction (MUO), we examined the effects of metallic ureteral stenting using the Cook Resonance® stent in the treatment of MUO. Methods All patients who had a Resonance metallic stent inserted between April 2015 and March 2018 at one of multiple facilities were prospectively observed with a 1-year follow-up. The primary outcome was the patency rate of the metallic ureteral stent. The secondary outcomes included the complications (e.g., infection and fever). Results Although stent insertion was attempted in 50 patients, the stent could not be inserted as a ureteral stent in three patients due to severe ureteral stricture, and one ureteral cancer patient was excluded from the analysis. The remaining 46 patients’ median age was 67 years (range 28–85 years) (16 males, 30 females). Twenty-four patients died during the study; their median survival time was 226 days. The median follow-up period for the censored patients was 355 days (range 16–372 days), and just seven patients were still alive without Resonance failure > 1 year later. The women’s IPSS scores tended to be lower than those of the men. Regarding the OABSS score, although the women’s total score tended to be low, the difference between the men’s and women’s scores was nonsignificant. The bacteria detected from urine culture after stent insertion were more gram-positive than gram-negative. Conclusion Metallic ureteric stenting using the Resonance stent is safe and effective for treating MUO. Subjective symptoms were relatively less in the female patients.
Databáze: OpenAIRE
Externí odkaz: